Skip to main content

About Our Products and Services

Your Trusted Comprehensive Genomic Profiling Partner

Foundation Medicine has the most experience with comprehensive genomic profiling in the industry.1 By partnering with biopharma and clinical stakeholders alike, we’ve developed an extensive genomic database and body of research that have strengthened the services we can offer all of our customers.

Health Care Providers

Our proven portfolio of tests and services brings in-depth genomic insights, experience, and a breadth of offerings into each practice we work with.

Learn more about products & services for providers

Biopharmaceutical Partners

We provide actionable insights into the genomics of both rare and common cancers, fueling discovery through commercialization by using a robust database and having deep experience with FDA approvals.

Learn more about biopharma partnerships

Foundation Facts & Figures

500k+

Patient Samples Profiled

500+

Peer-reviewed Publications

65+

Biopharma Partners

Recent Updates

FoundationOne®Liquid CDx

FoundationOne®Liquid CDx has been approved by the FDA as the only blood-based CGP companion diagnostic (CDx) for Tabrecta® (capmatinib). Our FDA-approved portfolio of both CGP tissue- and blood-based tests are now approved as the only CDx for Tabrecta® (capmatinib) in identifying advanced non-small cell lung cancer (NSCLC) patients having mutations that lead to METex14 skipping mutations and offers the highest number of CDx indications in NSCLC.

Learn more about FoundationOne Liquid CDx

FoundationOne®CDx

Our FoundationOne CDx tissue-based test has been approved as the only FDA-approved companion diagnostic to detect NTRK1/2/3 fusions for Vitrakvi® (larotrectinib).

Learn more about FoundationOne CDx

Additional Notes

1Data on file, Foundation Medicine, Inc, 2021

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. 

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.